Augmenix Looks To Apply Hydrogel Technology Beyond Prostate Cancer

The company's SpaceOAR injected hydrogel spacer continues to prove effective at reducing the collateral damage from radiation treatment for prostate cancer. Now the Boston company hopes to apply the same bioabsorbable hydrogel technology to improve outcomes with radiation therapy for other cancers, including pancreatic and gynecological cancer.

More from Clinical Trials

More from R&D